Targeted partnerships Collaborate with Systasy on neutrophil-derived inflammatory disease programs leveraging their proprietary barcoding technology for target identification, patient stratification, and biomarker-driven patient selection to accelerate co-developed therapies.

AI-driven data Leverage Systasy's AI-supported platform to enhance data quality for companion diagnostics, enabling more precise biomarker panels and faster market-ready diagnostic tools aligned with their drug discovery efforts.

Viral vector insights Offer services or products that complement Systasy's DNA barcoding for biodistribution and cell-type infectivity profiling across multiple viral serotypes, creating opportunities in gene therapy and vector safety assessments.

Clinical collaboration Engage with Systasy’s academic and hospital partnerships (e.g., LMU University Hospital Munich collaboration) to co-develop translational studies, access patient-derived models, and pilot feasibility projects.

Growth opportunity Position solutions that scale with their revenue trajectory (currently in the low-to-mid eight figures range) such as high-throughput screening analytics, data management, and regulatory-grade biomarker discovery services to support expansion and pipeline velocity.